The Quantellect read.As of Nov 20, 2026, 8 active firms cover Agios Pharm: 5 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $32.00 to $55.00, a moderate spread. The average target of $41.50 sits 44% above the current $28.76. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 131% this year and 108% next, consensus EPS building from about $-0.81 next quarter toward $-3.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy563%
Neutral338%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$41.50
+44.3% upside
Average target across 8 active firms as of Nov 20, 2026 vs $28.76 current
Highest Target$55.00
Average Target$41.50
Lowest Target$32.00
Detailed analyst forecasts for AGIO
Showing 1–9 of 9 named analysts shown · 8 active firms in the rating projection
As of Nov 20, 2026, 5 of 8 active firms rate AGIO a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AGIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.81
Range $-0.81 – $-0.81 · 1 analysts · -52% YoY
Next period, 1 analysts expect Agios Pharm to earn $-0.81 a share (range $-0.81 – $-0.81), versus $-1.69 a year earlier. Full-year consensus is $-5.56, growing to $-3.11 the year after.
REVENUE · NEXT QUARTER
$71.2M
Range $69.2M – $73.2M · 1 analysts · +167% YoY
Revenue is expected to reach $71.2M (range $69.2M – $73.2M), +167.0% year-over-year. Full-year consensus is $185.7M, rising to $345.5M next year.
Top analysts covering Agios Pharm
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AGIO.
#1
Luca Issi
RBC Capital · Rank #76
Neutral
$32.00+11.3% to target
Overall win rate
49%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #162
Buy
No targeton AGIO
Overall win rate
53%
+ Follow
#3
Greg Harrison
Scotiabank · Rank #223
Buy
$65.00+126.0% to target
Overall win rate
38%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #277
Buy
$57.00+98.2% to target
Overall win rate
35%
+ Follow
#5
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$52.00+80.8% to target
Overall win rate
41%
+ Follow
AGIO stock forecast FAQ
What is AGIO's average 12-month price target?+
The 8 active firms with a live target average $41.50 for Agios Pharm over the next 12 months, ranging from a $55.00 high to a $32.00 low, as of Nov 20, 2026.
Is AGIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 20, 2026, 5 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AGIO?+
The Street-high target is $55.00 (HC Wainwright & Co.), and the Street-low is $32.00 (RBC Capital). The average of all 8 active-firm targets is $41.50.
How many active Wall Street firms cover AGIO?+
8 active firms have a recognized rating on Agios Pharm as of Nov 20, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AGIO?+
Among analysts who currently cover AGIO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Neutral with a $32.00 target.
What is Agios Pharm's projected EPS for next quarter?+
The consensus estimate is $-0.81 per share (range $-0.81 – $-0.81) across 1 analysts. Full-year EPS is projected at $-5.56, rising to $-3.11 the following year.
How much revenue is Agios Pharm expected to report next quarter?+
Consensus revenue is $71.2M (range $69.2M – $73.2M). Full-year revenue is projected at $185.7M, growing to $345.5M next year.
Have analysts been upgrading or downgrading AGIO lately?+
As of Nov 20, 2026, 5 of 8 active firms rate AGIO a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AGIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.